Latest news with #EksoBionics
Business Insider
3 days ago
- Business
- Business Insider
Ekso Bionics trading halted, news pending
19:50 EDT Ekso Bionics (EKSO) trading halted, news pending Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Business Insider
20-05-2025
- Business
- Business Insider
Ekso Bionics to effect 1-for-15 reverse stock split
Ekso Bionics announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of May 27at 12:01 a.m. Pacific time. The company's common stock will open for trading on Nasdaq Capital Market on May 27 on a split-adjusted basis under the existing symbol (EKSO). The company's common stock will trade under a new CUSIP number 282644 400 upon the effectiveness of the reverse stock split. Upon the effectiveness of the reverse stock split, the number of shares of the company's outstanding common stock will decrease from approximately 35,289,695 pre-split shares to approximately 2,352,646 post-split shares, with no change in par value per share. The reverse stock split was approved by the company's shareholders at a special meeting held on May 16, 2025, and is primarily intended to raise the per share trading price of the Company's common stock and, in particular, enable the Company to regain compliance with the minimum bid price requirement for maintaining its listing on The Nasdaq Capital Market. To regain compliance, the closing bid price of the company's common stock must be at least $1.00 for a minimum of ten consecutive trading days. Confident Investing Starts Here:
Associated Press
15-05-2025
- Business
- Associated Press
Ekso Bionics Accepted into NVIDIA Connect Program
Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics' proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ('Ekso Bionics' or the 'Company'), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVIDIA Connect program. The Company plans to use the valuable tools and resources provided through this prestigious NVIDIA program to support a new strategic initiative to build a proprietary foundation model for human motion, and to help develop and integrate related new artificial intelligence ('AI') capabilities across its portfolio of Enterprise Health and Personal Health devices. NVIDIA Connect is a selective program that brings together emerging and established technology companies to accelerate product development and increase cost efficiency. Members gain specialized training, priority engineering support, and exclusive access to NVIDIA's advanced development kits, GPU platforms, and global ecosystem, helping facilitate the program members' ability to deliver next-generation solutions in AI and high-performance computing. 'We are privileged to join a select group of medical device innovators in the NVIDIA Connect program,' said Scott Davis, Chief Executive Officer of Ekso Bionics. 'While our advanced exoskeleton technology platforms are already state-of-the-art, in some ways we are only just approaching the starting line as we work to build and leverage what we believe will be the industry's first known foundation model for human motion in physical rehabilitation. We are excited for this journey with NVIDIA Connect and look forward to updating all of our stakeholders as we progress.' About Ekso Bionics® Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Based upon its industry-leading expertise, the Company focuses on improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol 'EKSO.' For more information, visit: Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding the plans, objectives and expectations of management with respect to the Company's industry, growth and strategy, including the Company's plan to build a proprietary model for human motion and the expected benefits of AI capabilities and being a part of the NVIDIA Connect program. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to realize the benefits of the NVIDIA Connect program or successfully complete the building of a proprietary model for human motion, the Company's inability develop and integrate related new AI capabilities across its portfolio, the Company's inability to obtain adequate financing to fund and grow the Company's operations and necessary to develop or enhance the Company's technology, the Company's inability to successfully collaborate with its network of existing neuro-rehabilitation facilities, physicians, and DMEs in seeking CMS reimbursements, the Company's inability to obtain future reimbursements from CMS in a timely manner and at the expected reimbursement levels, the Company's ability to raise funds to operate and grow its business, the Company's inability to obtain insurance coverage beyond CMS, the Company's inability to obtain additional indications of use for its devices, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of the Company's sales and marketing efforts or of partners to market the Company's products effectively, adverse results in future clinical studies of the Company's medical device products, the failure of the Company to obtain or maintain patent protection for the Company's technology, the failure of the Company to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, disruptions in the Company's supply chain, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's most recently filed Annual Report on Form 10-K and its subsequently filed Quarterly Reports on Form 10-Q. To learn more about Ekso Bionics please visit the Company's website at or refer to the Company's X page, formerly Twitter, at @EksoBionics. Any forward-looking statements made in this press release speak only as of the date of this press release. The Company does not undertake to update these forward-looking statements, except as required by law. Contact: Stephen Kilmer Investor Relations Direct: (646) 274-3580 Email: [email protected]
Yahoo
23-04-2025
- Business
- Yahoo
Bionic P&O Chosen as First Distributor of Ekso Indego® Personal Within the Orthotics & Prosthetics Industry
Alliance marks Ekso Bionics' first entrance into the O&P space SAN RAFAEL, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the 'Company'), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has named Bionic Prosthetics & Orthotics Group LLC ('Bionic P&O'), a leading national provider of prosthetic and orthotic solutions, as a non-exclusive Ekso Indego® Personal device distributor. Ekso Indego Personal is a wearable lower extremity powered exoskeleton that enables certain individuals living with spinal cord injuries ('SCIs') with the ability to stand and walk independently. It is the only known portable exoskeleton device to offer a modular quick connect design, which was engineered to allow users to put on and take off the device without assistance. Ekso Indego Personal is the lightest known commercial exoskeleton available offering ease of handling, transportation, and storage. Also offering an advanced gait mode, individuals with a SCI using the device have been shown to reach faster walking speeds, granting them a new level of independence in the community. 'This exciting new commercial alliance with a recognized leader like Bionic P&O aligns squarely with our mission of improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function,' commented Scott Davis, the Company's Chief Executive Officer. 'From a business perspective, the successful marketing and distribution of an innovative device like Ekso Indego Personal requires deep insight into the particular market dynamics, the reimbursement landscape, and above all, the needs of patients served within the community. I cannot think of a better choice than Bionic P&O as our first distributor for Ekso Indego Personal within the important orthotics and prosthetics industry.' 'True innovation that supports patients in reaching their goals, paired with compassionate care, is the cornerstone of Bionic P&O's success. Bionic P&O's mission is to empower individuals to live more independent and fulfilling lives. We believe the Ekso Indego Personal device will make a lasting positive impact on our patients' lives and has the potential to transform the orthotics and prosthetics industry,' said Daniel Chan, National Business Development Manager at Bionic P&O. 'We are thrilled by our alliance with Ekso Bionics. Together, we are paving the way for a future where spinal cord injury patients can not only dream of walking again, but actively work towards that goal.' About Ekso Bionics®Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Based upon its industry-leading expertise, the Company focuses on improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol 'EKSO.' For more information, visit: About Bionic P&OFounded in 2007, Bionic P&O is an independent clinical practice group that now operates across 12 states: Florida, Illinois, Indiana, Kentucky, Michigan, New Jersey, North Carolina, Ohio, Pennsylvania, Tennessee, Texas, and Wisconsin. Fully accredited by the American Board for Certification in Orthotics, Prosthetics, and Pedorthics (ABC), Bionic P&O employs certified/licensed O&P practitioners with expertise in a wide range of specialties, including advanced lower and upper limb prosthetics, lower and upper limb orthotics, spinal orthotics, pediatric orthotics, and cranial remolding orthotics. For more information, visit: Forward-Looking StatementsAny statement contained in this press release that does not describe historical facts may constitute a forward-looking statement. Forward-looking statements may include, without limitation, statements regarding the ability of Bionic P&O to distribute the Company's Ekso Indego Personal device within the orthotics and prosthetics products industry in the United States, the impact to the Company and the broader industry of the Company's partnership with Bionic P&O, the potential impacts of the Company's device to patients using the device, and the Company's ability to bolster demand for its technology and execute on its long-term growth strategy. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund and grow the Company's operations and to develop or enhance the Company's technology, the Company's inability to obtain future reimbursements from CMS in a timely manner and at the expected reimbursement levels, the Company's inability to obtain insurance coverage beyond CMS, the Company's inability to obtain additional indications of use for its devices, any delay or discontinuation of the sales and distribution of Esko Indego Personal within the orthotics and prosthetics products industry, or Ekso Indego Personal risks related to product liability, recall and warranty claims. These and other factors are identified and described in more detail in the Company's filings with the U.S. Securities and Exchange Commission. To learn more about Ekso Bionics please visit the Company's website at or follow @EksoBionics on X. The Company does not undertake to update these forward-looking statements, except as required by law. Contact:Stephen KilmerInvestor RelationsDirect: (646) 274-3580Email: skilmer@ in to access your portfolio
Yahoo
24-02-2025
- Business
- Yahoo
Ekso Bionics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3 – Conference Call to Follow
SAN RAFAEL, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the 'Company'), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2024 after the close of trading on Monday, March 3, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company's website at under 'Presentations & Events' in the Investors section. About Ekso Bionics®Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol 'EKSO.' For more information, visit: or follow @EksoBionics on X. Contact:Stephen KilmerInvestor RelationsDirect: (646) 274-3580Email: skilmer@ in to access your portfolio
